drug
aspirin
Marketedupdated 3mo agoby $ASBP Aspire Biopharma Holdings, Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE335 co-mentions · 107 sources
- tagApproval316 co-mentions · 104 sources
- drugSYNALGOS-DC288 co-mentions · 107 sources
- drugStem Cell Therapy for Coronavirus Disease 2019 (COVID-19)269 co-mentions · 107 sources
- tagSmall Molecule158 co-mentions · 104 sources
- drugcodeine94 co-mentions · 47 sources
- drugPROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE94 co-mentions · 47 sources
- drugPROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE94 co-mentions · 47 sources
all catalysts(0)
nothing on the calendar yet
Trials studying aspirin
- phase2Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
- phase3Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
- N/AThromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
- phase1Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects
- N/AHighest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients
- phase2Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
- phase2Mechanisms of Dupilumab in AERD
- phase1The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 29, 2032
~6.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Sep 29, 2032formulationUS 10646431
- Sep 29, 2032formulationUS 10646431
- Sep 29, 2032method-of-use (U-3559)US 10786444
- Sep 29, 2032method-of-use (U-3559)US 10786444
- Sep 29, 2032formulationUS 9216150
- Sep 29, 2032method-of-use (U-1732)US 9226892
News(2)
- Dr Jones on the Protective Benefit and Tolerability of GLP-1 Agonists vs Aspirin for CRC PreventionColton Jones, MD, shares data from a retrospective analysis of GLP-1 receptor agonists vs aspirin for the primary prevention of colorectal cancer.onclive · 3mo ago
- Predicting consequences of new hepatitis B vaccine recsNew data on public trust in science, AI and mental health, and other news from Morning Roundsstat · 3mo ago
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that